拉米夫定与α-干扰素治疗慢性乙型肝炎的疗效对比  

Comparison of Lamivudine and Alpha-interferon for Chronic Hepatitis B

作　　者：龙涛[1] 徐龙[1] 徐贞秋[1] 付军[1] 

机构地区：[1]南昌市第九医院肝二科,南昌330002

出　　处：《实用临床医学（江西）》2012年第7期11-12,27,共3页Practical Clinical Medicine

摘　　要：目的比较α-干扰素与拉米夫定治疗慢性乙型肝炎的疗效。方法将100例慢性乙型肝炎患者按随机数字表法分为2组。研究组:拉米夫定100 mg.d-1,口服,1次.d-1;对照组:α-干扰素5 mU,肌内注射,隔日1次。2组疗程均为12个月。结果研究组丙氨酸转氨酶恢复正常率、HBV-DNA转阴率明显高于对照组,2组比较差异有统计学意义(P<0.05)。2组HBeAg血清学转换率差异无统计学意义(P>0.05)。结论拉米夫定较α-干扰素有更好的抗病毒效果。Objective To compare the curative effects of alpha-interferon（α-IFN） and lamivudine on chronic hepatitis B.Methods One hundred patients with chronic hepatitis B were randomly assigned to receive either oral lamivudine 100 mg/day once daily or intramuscular injection of α-IFN 5 mU twice daily.The treatment course was 12 months.Results The rate of alanine transaminase returning to normal and the negative conversion rate of HBV-DNA in lamivudine treatment group were significantly higher than those in α-IFN treatment group（P0.05）.Conclusion Lamivudine has better antiviral efficacy than α-IFN.

关 键 词：乙型肝炎 慢性 Α-干扰素 拉米夫定 

分 类 号：R512.6[医药卫生—内科学]